Richard Klausner - Jun 21, 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Executive Chairman, Director
Signature
/s/ Heather Turner, as Attorney-in-fact
Stock symbol
LYEL
Transactions as of
Jun 21, 2021
Transactions value $
$0
Form type
4
Date filed
6/23/2021, 05:36 PM
Previous filing
Jun 16, 2021
Next filing
Sep 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Conversion of derivative security +3.77M 3.77M Jun 21, 2021 Lyell Investors, LLC F1, F2
holding LYEL Common Stock 2.97M Jun 21, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Series A Convertible Preferred Stock Conversion of derivative security $0 -3.77M -100% $0.00* 0 Jun 21, 2021 Common Stock 3.77M Lyell Investors, LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.
F2 The Reporting Person is a manager of Lyell Investors, LLC (Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein